Value of GlutathioneS-Transferase π and the Oncogene Products c-Jun, c-Fos, c-H-Ras, and c-Myc as a Prognostic Indicator in Endometrial Carcinomas

Objective.To examine the relationship between the expressions of glutathioneS-transferase π (GST-π) and four oncogene products, c-Jun, c-Fos, c-H-Ras, and c-Myc, and clinicopathological prognostic factors and patients' prognosis in endometrial carcinomas, and to assess their prognostic value in endometrial carcinomas.Methods.Specimens of endometrial carcinoma obtained from 63 patients were investigated immunohistochemically using respective specific antibodies.Results.The overall positive rates in 63 carcinoma specimens were 34.9% for GST-π, 44.4% for c-Jun, 34.9% for c-Fos, 47.6% for c-H-Ras, and 54.0% for c-Myc. Multivariate analysis revealed that GST-π expression correlated independently with paraaortic lymph node (PAN) metastasis, and c-Jun expression was independently related to pelvic lymph node (PLN) and PAN metastasis. The prognosis of patients with a GST-π-positive tumor was significantly poorer than that of those with a GST-π-negative tumor (P< 0.05). The patients with c-Jun-positive tumor also had a significantly worse prognosis than those with c-Jun-negative tumor (P< 0.05). No significant relationship between the expressions of the remaining three oncogene products, c-Fos, c-H-Ras, and c-Myc, and the examined prognostic factors and clinical outcome was apparent.Conclusion.These results suggest that the expressions of GST-π and c-Jun may reflect the metastatic potential of endometrial carcinomas and that their expressions of endometrial carcinoma may be useful as a prognostic indicator for predictive testing.